Skip to content

Loeb Partner Jim Czaban Recognized in Who's Who Legal Thought Leaders: Global Elite 2022

Loeb & Loeb is pleased to announce that Food & Drug Administration partner Jim Czaban has, for the third year in a row, been named as a 2022 Global Elite Thought Leader by Who’s Who Legal (WWL) in the Life Sciences – Regulatory category. Jim is one of just four U.S.-based lawyers to receive the recognition in the Life Sciences - Regulatory category. In particular, the publication notes that Jim "is highly esteemed among peers for his 'excellent work' and 'strong regulatory expertise.'" WWL has previously recognized Jim as “a key player in the life sciences sector, who sources highlight for his remarkable understanding of regulatory compliance issues” (2021), and as “one of the market’s leading minds, with ‘very well-rounded expertise’” (2020).

WWL Thought Leaders: Global Elite brings together the insight, expertise and wisdom of some of the world’s foremost lawyers and experts in a single report. Through interviews with the practitioners themselves, Thought Leaders: Global Elite aims to shine a light on what puts these lawyers and experts at the peak of the profession. They are worthy of special mention owing not only to their vast expertise and experience advising on some of the world’s most significant and cutting-edge legal matters, but also their ability to innovate, inspire, and go above and beyond to deliver for their clients.

Based in Washington, DC, Jim Czaban is a leading FDA regulatory and compliance lawyer with 30 years' experience in government regulation of pharmaceutical, biotechnology, food, medical device and life sciences related companies. He focuses his practice on counseling such clients on complex regulatory strategies and compliance matters, as well as representing clients in administrative and judicial enforcement actions and other proceedings involving the Food & Drug Administration, the Federal Trade Commission, the Drug Enforcement Administration, the Department of Justice and other federal and state agencies.